ARTICLE | Product Development

GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute

Plus SAB gets additional funding from U.S. government, starts human trials

August 13, 2020 1:48 AM UTC

GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma. 

GigaGen Inc. plans to submit an IND for its COVID-19 treatment, GIGA-2050, by year-end...